Edition:
India

Gamida Cell Ltd (GMDA.OQ)

GMDA.OQ on NASDAQ Stock Exchange Global Market

5.00USD
18 Oct 2019
Change (% chg)

-- (--)
Prev Close
$5.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,476
52-wk High
$15.41
52-wk Low
$2.93

Latest Key Developments (Source: Significant Developments)

Gamida Cell Announces Launch Of Proposed Public Offering Of Ordinary Shares
Tuesday, 25 Jun 2019 

June 24 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING OF ORDINARY SHARES.GAMIDA CELL LTD - LAUNCH OF A PROPOSED FOLLOW-ON PUBLIC OFFERING OF APPROXIMATELY $30.0 MILLION OF ITS ORDINARY SHARES..GAMIDA CELL LTD - GAMIDA CELL EXPECTS TO GRANT UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO $4.5 MILLION OF ADDITIONAL ORDINARY SHARES.  Full Article

Gamida Cell Ltd Files For Offering Of 4.04 Million Ordinary Shares - SEC Filing
Tuesday, 25 Jun 2019 

June 24 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL LTD FILES FOR OFFERING OF 4.04 MILLION ORDINARY SHARES - SEC FILING.  Full Article

Gamida Cell And Lonza Establish Commercial Manufacturing Agreement For Omidubicel
Wednesday, 19 Jun 2019 

June 19 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL AND LONZA ESTABLISH COMMERCIAL MANUFACTURING AGREEMENT FOR OMIDUBICEL.AGREEMENT PROVIDES FOR FUTURE COMMERCIAL PRODUCTION AFTER POTENTIAL FDA APPROVAL OF OMIDUBICEL.  Full Article

Gamida Cell Reports First Quarter 2019 Financial Results And Provides Company Update
Tuesday, 7 May 2019 

May 7 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.GAMIDA CELL LTD - GAMIDA CELL CONTINUES TO EXPECT CASH USED FOR ONGOING OPERATING ACTIVITIES IN 2019 TO RANGE FROM $35-$40 MILLION.GAMIDA CELL - AS OF MARCH 31, CO HAD TOTAL CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE SECURITIES OF $50.3 MILLION, COMPARED TO $60.7 MILLION AS OF DECEMBER 31, 2018.GAMIDA CELL LTD - NET LOSS FOR Q1 WAS $15.5 MILLION, COMPARED TO A NET LOSS OF $7.4 MILLION IN SAME PERIOD IN 2018.GAMIDA CELL LTD - INITIATE MULTI-CENTER, PHASE 1/2 CLINICAL STUDY IN PATIENTS WITH NHL IN 2020.  Full Article

Gamida Cell Announces Agreement With Editas Medicine To Evaluate Use Of CRISPR Genome Editing Technology In NAM-NK Cells
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL ANNOUNCES AGREEMENT WITH EDITAS MEDICINE TO EVALUATE USE OF CRISPR GENOME EDITING TECHNOLOGY IN NAM-NK CELLS.GAMIDA - CO, EDITAS MEDICINE WILL ENGAGE IN JOINT RESEARCH TO EVALUATE UNNAMED TARGETS NAM-BASED CELL EXPANSION TECHNOLOGY WITH CRISPR TECHNOLOGY.  Full Article

Gamida Cell And Be The Match Biotherapies® Announce Strategic Collaboration
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Gamida Cell Ltd ::GAMIDA CELL AND BE THE MATCH BIOTHERAPIES® ANNOUNCE STRATEGIC COLLABORATION.GAMIDA CELL LTD - COLLABORATION AIMS TO EXPAND USE OF BONE MARROW TRANSPLANT TO TREAT HEMATOLOGIC MALIGNANCIES AND SERIOUS BLOOD DISORDERS.GAMIDA CELL LTD - COLLABORATION IS EXPECTED TO LEVERAGE A WIDE RANGE OF BE MATCH BIOTHERAPIES' RESEARCH ASSETS AND SERVICES.  Full Article